- Home
- GRABW vs MIRM Comparison
GRABW vs MIRM Comparison
Compare GRABW & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRABW
- MIRM
- Stock Information
- Founded
- GRABW 2012
- MIRM 2018
- Country
- GRABW Singapore
- MIRM United States
- Employees
- GRABW 11267
- MIRM N/A
- Industry
- GRABW Business Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- GRABW Consumer Discretionary
- MIRM Health Care
- Exchange
- GRABW Nasdaq
- MIRM Nasdaq
- Market Cap
- GRABW N/A
- MIRM 1.9B
- IPO Year
- GRABW N/A
- MIRM 2019
- Fundamental
- Price
- GRABW $0.34
- MIRM $38.96
- Analyst Decision
- GRABW
- MIRM Strong Buy
- Analyst Count
- GRABW 0
- MIRM 11
- Target Price
- GRABW N/A
- MIRM $58.55
- AVG Volume (30 Days)
- GRABW 54.7K
- MIRM 439.1K
- Earning Date
- GRABW 02-21-2025
- MIRM 05-07-2025
- Dividend Yield
- GRABW N/A
- MIRM N/A
- EPS Growth
- GRABW N/A
- MIRM N/A
- EPS
- GRABW N/A
- MIRM N/A
- Revenue
- GRABW $2,686,000,000.00
- MIRM $336,888,000.00
- Revenue This Year
- GRABW N/A
- MIRM $29.51
- Revenue Next Year
- GRABW N/A
- MIRM $20.27
- P/E Ratio
- GRABW N/A
- MIRM N/A
- Revenue Growth
- GRABW 21.65
- MIRM 80.76
- 52 Week Low
- GRABW $0.15
- MIRM $23.14
- 52 Week High
- GRABW $0.59
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- GRABW 42.35
- MIRM 32.65
- Support Level
- GRABW $0.31
- MIRM $37.83
- Resistance Level
- GRABW $0.33
- MIRM $40.32
- Average True Range (ATR)
- GRABW 0.05
- MIRM 2.47
- MACD
- GRABW -0.00
- MIRM -0.28
- Stochastic Oscillator
- GRABW 20.13
- MIRM 17.20
About GRABW Grab Holdings Limited Warrant
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore and Malaysia contributed 58% of revenue as of end-2021. Grab's main competitors in Southeast Asia are Foodpanda and Gojek, the ride-sharing arm of GoTo. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.